

**Supplementary Table 6.** Hazard ratios for cardiovascular events in the subgroup with available health examination data after propensity score matching

Variable	Cohort 1 ( <i>n</i> =9,205 pairs)			Cohort 2 ( <i>n</i> =7,998 pairs)		
	Event rate		HR (95% CI)	Event rate		HR (95% CI)
	SGLT2i	DPP-4i		SGLT2i	SU	
HHF	0.61	0.72	0.84 (0.59–1.21)	0.62	0.91	0.68 (0.48–0.97)
All-cause death	0.31	0.29	1.06 (0.62–1.81)	0.34	0.37	0.92 (0.55–1.53)
HHF+All-cause death	0.84	0.97	0.86 (0.63–1.17)	0.88	1.21	0.73 (0.54–0.99)
Myocardial infarction	0.19	0.24	0.83 (0.44–1.56)	0.20	0.40	0.52 (0.29–0.94)
Stroke	0.86	0.86	0.99 (0.72–1.36)	0.89	0.87	1.02 (0.74–1.42)
modified MACE	1.26	1.34	0.94 (0.73–1.21)	1.33	1.50	0.88 (0.68–1.14)

Above results were obtained by intention to treatment analyses.

SGLT2i, sodium glucose cotransporter 2 inhibitor; DPP-4i, dipeptidyl peptidase-4 inhibitor; HR, hazard ratio; CI, confidence interval; SU, sulfonylurea; HHF, hospitalization for heart failure; MACE, modified major adverse cardiovascular event.